Viral hepatitis B (HBV) is a major health problem in Saudi Arabia and worldwide. HBV infection chronically afflicts 240 million people while more than 780 000 people die annually due to complications.[@b1-asm-4-272] The picture is similar for hepatitis C (HCV) with 130--150 million people infected and 500 000 people dying every year from hepatitis C infection.[@b2-asm-4-272] In Saudi Arabia, HBV infection was hyperendemic.[@b3-asm-4-272] Three decades ago HBV prevalence was 7% in the first epidemiological study of Saudi children.[@b4-asm-4-272] The country addressed the issue in a serious manner, and hepatitis B vaccination become a part of the mandatory vaccination program in the country in 1989.[@b5-asm-4-272] Screening for HBV and HCV is currently part of the premarital screening program.[@b6-asm-4-272] HIV, HBV and HCV infections were first tested in premarital screening in January 2008. The aim of testing is not to prevent marriage of discordant couples, but to provide them with information and education to prevent transmission of infection. Since 2008, several studies have shown a major reduction in HBsAg prevalence to negligible values in children, indicating the success of the HBV vaccine program.[@b7-asm-4-272]--[@b10-asm-4-272]

In assisted reproduction, there is a concern about transmission of the infection to newborns and to medical or laboratory staff, as well as cross-contamination of other virus-free gametes or embryos in cryocontainers during storage.[@b11-asm-4-272]--[@b15-asm-4-272] In in vitro fertilisation (IVF) programs, couples are tested routinely for HCV and HBV to reduce the potential risk for transmission in the same laboratory, especially during cryopreservation of embryos.[@b16-asm-4-272] Studies of HBV and HCV prevalence in the IVF population have mostly focused on pregnancy outcomes.[@b17-asm-4-272]--[@b19-asm-4-272] Other studies have demonstrated the effect of viral infection on male and female fertility.[@b20-asm-4-272]--[@b22-asm-4-272] Only a few studies have addressed prevalence of hepatitis in infertile patients.[@b23-asm-4-272] One study by Mansoor et al conducted in Saudi Arabia between 2006 and 2008 reported an overall prevalence of 1.8% for HBV.[@b24-asm-4-272] The overall HCV prevalence in the same group was 0.5%. The aim of our study was to determine the prevalence of HCV and HBV in the IVF population in Saudi Arabia between years 2012--2015 and compare it with the prevalence 10 years earlier in the same population.

PATIENTS AND METHODS
====================

In this retrospective study, data was collected on HBV and HCV prevalence for all couples seen at the IVF unit, King Faisal Hospital and Research Centre in Riyadh, between 2002--2005 and 2012--2015. The study was approved by KFSHRC Institutional Review Board. If the hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) were positive, the patient was considered hepatitis B seropositive. For HCV, couples were tested for HCV antibodies or by recombinant immunoblot assay (RIBA). The chi-square test was used to test for statistically significant differences and for trends. A *P* value \<.05 was considered statistically significant.

RESULT
======

For 4442 patients during 2002--2005 and 5747 patients during 2012--2015, there were significantly more HBV positive patients in the period from 2002--2005 (210 positive, 4.7%) compared to 2012--2015 (97 positive, 1.6 %) *P*\<.0001) ([Table 1](#t1-asm-4-272){ref-type="table"}). However, the seropositivity rate for HCV was not different between the two study periods (*P*=.887). HBV seropositivity was significantly higher in males compared to females in for both periods (6.3% vs 3.1% and 2.4% vs 1.1%, respectively, *P*\<.0001) ([Table 2](#t2-asm-4-272){ref-type="table"}). Seropositivity for HCV between the two genders was not significantly different ([Table 2](#t2-asm-4-272){ref-type="table"}).

DISCUSSION
==========

The present study shows that the prevalence of HBV during 2012--2015 (1.67%) was low as defined by the WHO. This seroprevalence was similar to other studies conducted about the same period in Saudi Arabia, as in Mansoor et al in infertile Saudi couples between 2006 and 2008, which reported an overall prevalence of 1.8% for HBV in the study population.[@b24-asm-4-272] In addition, HBV prevalence was 1.3% in premarital screening data for 2008.[@b6-asm-4-272] We noticed a major decline in HBV prevalence compared to results 10 years earlier when the seroprevalence was 4.7%. This dramatic change in HBV prevalence in Saudi Arabia is attributed to several factors such as improvement in health care facilities, better socioeconomic status, and the successful vaccination program against HBV. However, this decline in the prevalence of HBV reached a steady state between 2008 and 2015. More studies are needed to assess whether there is a further decline in HBV prevalence.

HCV prevalence in our study remained about the same during the last 10 years, with a seroprevalence rate of 0.7% ifor both periods. Why the change in HCV prevalence is different than HBV is unclear. The difference is most likely due to lack of a large community-based study to estimate the true prevalence of HCV in the country. The prevalence in Saudi blood donors was estimated to be 0.4--1.1%.[@b25-asm-4-272]--[@b27-asm-4-272] The premarital screening program showed an HCV prevalence of 0.33%.[@b6-asm-4-272] These different seroprevalence results are due to different populations in each study. Better socioeconomic status, and improvement in health care facilities, especially after introduction of blood screening program in Saudi Arabia in the early 1990s, helped reduce the prevalence of HCV at that period. That period was not included in our study. Afterwards, HCV prevalence remained constant in Saudi Arabia.[@b27-asm-4-272] Unlike HBV prevalence, which declined mainly due to the availability of HBV vaccine, implementation of HCV vaccination is under development. A national screening program, increased public awareness of HCV transmission, and a new generation drugs to treat HCV infection, may help to reduce the prevalence in future.

There was an obvious difference in HBV prevalence between males and females in Saudi Arabia.[@b28-asm-4-272] In our study, the incidence of HBV seropositivity showed a higher prevalence of HBV infection in males vs. females during both time periods. This difference has been observed in several studies.[@b28-asm-4-272],[@b29-asm-4-272] There is no clear explanation for the gender variation. The difference is probably related to the conservative society with less female exposure outside the family, but may also be due to opposite effects of sex hormones. In several experimental animal models, viral transcription is stimulated by androgen, while estrogen suppresses HBV transcription.[@b30-asm-4-272] In HCV seroprevalence there were no male vs female differences (0.8% vs 0.5%, and 0.7% vs 0.6%) between 2002--2005 and 2012--2015.

Our data suggest that viral hepatitis remains a major health problem in Saudi Arabia and that continued observation and monitoring are important to evaluate disease prevalence and the impact of new health program interventions. In assisted reproductive centres offering care for patients who are carriers of HBV and HCV, there is a need for more comprehensive preventive strategies and prevention of cross contamination. The issue of being a carrier is important for embryo freezing. Once infection is confirmed some centres do not freeze while others use separate cryocontainers to avoid cross contamination. Our data is the first in the country in the reproductive population showing the patterns of HBV and HCV and comparing the prevalence between two periods of time. The data show a significant decline in HBV prevalence among reproductive age patients, which was most likely due to vaccination, while HCV prevalence was unchanged from 10 years earlier. A limitation of the study was that no data was collected on confounding factors that may have affected the prevalence.
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###### 

Prevalence of hepatitis B and C virus in the study population.

  ---------------------------------------------
        2002--2005\   2012--2015\   *P* value
        n (%)         n (%)         
  ----- ------------- ------------- -----------
  HBV   210 (4.7)     97 (1.68)     .0001

  HCV   32 (0.7)      40 (0.7)      .887
  ---------------------------------------------

HBV-hepatitis B virus, HCV-hepatitis C virus.

###### 

Prevalence of hepatitis B and C virus in study population by sex.

  ---------------------------------------------------
                   Male\       Female\    *P* value
                   n (%)       n (%)      
  ---------------- ----------- ---------- -----------
  **2002--2005**                          

   HBV             141 (6.3)   69(3.1)    \<.0001

   HCV             19 (0.8)    13(0.59)   .287

  **2012--2015**                          

   HBV             61 (2.5)    36 (1.1)   \<.0001

   HCV             17 (0.68)   23 (0.7)   .92
  ---------------------------------------------------

HBV-hepatitis B virus, HCV-hepatitis C virus.
